[{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune Completes Dosing of First Cohort in Phase 1\/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune First Patient Dosed in NexImmune Phase 1\/2 Clinical Trial of NEXI-002 in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune to Highlight Preliminary Results from Phase 1\/2 Trial of NEXI-001 via Oral Presentation at 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"NexImmune","sponsor":"The Laura and Isaac Perlmutter Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NexImmune Announces Melanoma Research Collaboration with NYU Langone\u2019s Perlmutter Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"NexImmune","sponsor":"Columbia University Irving Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center\u2019s Herbert Irving Comprehensive Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"NexImmune","sponsor":"JDRF","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"NexImmune","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"NexImmune","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery"},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company\u2019s AIM Platform to Treat Viral Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"NexImmune","sponsor":"JDRF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery"}]
Find Clinical Drug Pipeline Developments & Deals by NexImmune
The partnership aims to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb,a murine surrogate of teplizumab, to tolerize, deplete or modulate diabetes antigen-specific T cells.
NEXI-004 is a patient derived stem cell developed using adoptive cell therapy modality technology which is being developed for EBV associated diseases. It is currently in preclinical stage of development.
The goal of this collaboration is to develop adoptive cell therapies that may benefit patients afflicted with immunological disorders related to Epstein-Barr virus (EBV) and Human T-cell Leukemia Virus, type 1 (HTLV-1).
The agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) that have the potential to increase immunotherapy options for patients.
Lead Product(s):
HLA IgG4 Fusion Proteins,T-cell Co-stimulatory Monoclonal Antibodies
IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in patients with relapsed or refractory human papillomavirus (HPV)-related cancers.
The JDRF award will fund efforts to investigate the use of NexImmune’s AIM nanoparticles in combination with a murine surrogate of teplizumab. The investigation will test this hypothesis in a preclinical model by combining anti-CD3 mAb treatment.
Lead Product(s):
T1D Antigen-specific Nanoparticle,Teplizumab
The research will focus on the use of NexImmune’s adoptive cell therapy, AIM ACT, in Columbia’s patient-derived organoid (PDO) models of HPV-associated cancers, including head and neck squamous cell carcinoma.
The collaboration is centered around NexImmune’s artificial antigen presenting cells' (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients.
Preliminary data from its first-in-human study of NEXI-001, a multi-antigen specific CD8+ T cell product, in acute myeloid leukemia (AML) patients with relapsed disease has been selected for an oral presentation at the 62nd ASH Annual Meeting.
NEXI-002 is a patient-derived cellular product that contains populations of naturally-occurring CD8+ T cells directed against several multiple myeloma (MM)-specific antigen targets. It is the second clinical product NexImmune has generated with its AIM nanoparticle technology.